BPC-157 in Australia: TGA Schedule 4 Status and Research Guide (2026)

This guide covers the Australian regulatory landscape for BPC-157 as of mid-2026, with particular focus on the June 2024 TGA Schedule 4 rescheduling that changed the compound's status from unscheduled to Prescription Only. It is intended for Australian researchers who need a current, sourced account of the regulatory history, what changed, and what that means for research-grade access.

"The TGA's June 2024 decision placed BPC-157 in Schedule 4 on precautionary grounds: the compound had no completed human clinical trials, yet was being used at scale without medical supervision. The rationale was the absence of evidence supporting unsupervised use, not the presence of documented harm."
, RetaLABS Research Team, June 2026

This guide does not duplicate the mechanistic and preclinical science covered in the BPC-157 Research Guide or the structural chemistry in the BPC-157 Molecular Profile. Those resources cover mechanism of action, tissue repair evidence, and reconstitution protocols. This guide is specifically about the Australian regulatory position.

Compiled by the RetaLABS Research Team from TGA documentation and primary sources. All products referenced are for laboratory research use only.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It is derived from a sequence associated with human gastric juice and has been studied in preclinical models for effects on tendon repair, gastrointestinal healing, and angiogenesis. As of 2026, no human randomised controlled trial has been completed for any indication.

For detailed coverage of BPC-157's mechanism of action, musculoskeletal and gastrointestinal research evidence, and reconstitution protocols, see the BPC-157 Research Guide. For molecular weight, CAS number, sequence, and chemical identifiers, see the BPC-157 Molecular Profile. This guide focuses exclusively on the Australian regulatory context.

Prior to June 2024, BPC-157 held no scheduled status under Australia's Poisons Standard. As an unscheduled compound, it was not listed in any Schedule of the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP), meaning it fell outside the controlled-substance framework that governs pharmaceuticals, prescription medicines, and restricted chemicals.

In practical terms, unscheduled status meant:

• No prescription was required to purchase or possess BPC-157
• No explicit prohibition on sale existed under scheduling law, though general therapeutic goods advertising rules applied
• The compound was not listed on the ARTG as an approved product; it was neither approved nor prohibited under scheduling
• Supply was occurring through channels outside the regulated pharmaceutical supply chain, including online peptide suppliers servicing the Australian market

The TGA had not at that point completed a formal assessment of BPC-157 for any therapeutic indication. The compound's unscheduled status reflected the absence of a completed scheduling review, not an affirmative finding of safety or efficacy. The clinical trial pipeline for BPC-157 in humans remained at Phase 1 stage only, with no completed efficacy trials in any jurisdiction.

Meanwhile, use of BPC-157 in Australia had grown substantially, particularly in sports medicine, recovery, and general wellness contexts, driven by online communities and anecdotal reports drawn from the preclinical animal literature. The TGA monitored this trend as part of its ongoing scheduling reviews of emerging research compounds.

In June 2024, the TGA rescheduled BPC-157 from unscheduled to Schedule 4 (Prescription Only Medicine) under the Poisons Standard. The rescheduling was implemented as part of a broader instrument affecting research peptides that had moved into widespread unsupervised human use without completing the clinical trial pathway required for therapeutic approval.

The TGA's stated rationale centred on two factors:

1. Absence of completed human clinical trials. BPC-157 had not completed any Phase 2 or Phase 3 randomised controlled trial for any therapeutic indication. The highest stage of formal development was Phase 1, with no publicly registered efficacy trial having reached primary endpoint readout. The TGA's position was that a compound being used at scale therapeutically should have human trial data to assess its safety and efficacy profile in people.
2. Widespread unsupervised therapeutic use. The TGA observed that BPC-157 was being used by Australians outside any medical supervision framework, with users self-administering based on animal study data and online community guidance. This pattern, involving injectable administration of an uncharacterised compound without clinical oversight, was the precautionary basis for scheduling intervention.

Critically, the TGA's rationale was precautionary: the scheduling was not triggered by a specific adverse event or harm signal associated with BPC-157 use. There is no documented Australian case series of adverse events from BPC-157 that precipitated the review. The review was driven by the regulatory framework position that uncharacterised injectable compounds being used therapeutically at population scale warrant scheduling controls, regardless of whether harm has been documented.

TB-500 (Thymosin Beta-4, in both the strict heptapeptide and full 43-residue forms) was rescheduled simultaneously in the same June 2024 instrument, reflecting the same rationale: widespread unsupervised injectable use without completed human trials. The co-scheduling of BPC-157 and TB-500 was not coincidental; both compounds had developed parallel markets in Australian sports and recovery communities and were reviewed together.

Schedule 4 (Prescription Only Medicine) is the standard scheduling tier for pharmaceutical drugs in Australia that require medical oversight. Most antibiotics, antidepressants, and common prescription medications sit in Schedule 4.

For BPC-157 specifically, Schedule 4 status as of June 2024 means:

• Prescription required for therapeutic use. A registered Australian medical practitioner must write a prescription for BPC-157 to be legally supplied as a therapeutic agent, including to compounding pharmacies that formulate BPC-157 for patients.
• Compounding pharmacies can fill prescriptions. Schedule 4 status does not prohibit compounding pharmacies from preparing BPC-157 for individual patients if a valid prescription exists. The compound remains accessible through this pathway with appropriate medical authorisation.
• No TGA-approved product exists. BPC-157 is not listed on the ARTG. No manufacturer has obtained TGA approval of a BPC-157 product for any indication. The scheduling change does not create an approved product; it governs the conditions under which the compound can be supplied therapeutically.
• Research-grade supply framework. The scheduling of BPC-157 as a therapeutic good applies to its therapeutic supply. Research-grade supply for confirmed laboratory research use operates under the broader research framework. Researchers should verify their specific institutional and ethics requirements with their ethics committee or institutional biosafety officer.

For the broader legal framework governing research peptides in Australia, see the Research Peptides Legal Status in Australia guide.

While Australia moved to tighten BPC-157 scheduling in June 2024, the regulatory trajectory in the United States has taken a different direction, creating a notable divergence in the global research compound landscape.

In April 2026, the US Food and Drug Administration removed BPC-157 from its Category 2 list under the 503A and 503B compounding pharmacy frameworks. The Category 2 classification under FDA guidance identified substances that may be used in compounding for specific circumstances; removal from that list affects the conditions under which US compounding pharmacies can include BPC-157 in formulations.

The Australia-US regulatory divergence on BPC-157 is significant for researchers tracking the compound's global status:

Neither jurisdiction has approved BPC-157 as a therapeutic, and neither has a completed human efficacy trial. The two regulatory bodies have taken different approaches to managing a compound with substantial preclinical data but no human trial evidence, in the context of growing unsupervised use. Australian researchers should apply the TGA framework to their work and not draw operational conclusions from the US regulatory position.

RetaLABS supplies BPC-157 as a research-grade lyophilised peptide for laboratory use only. The BPC-157 20mg vial is available to Australian researchers with per-batch HPLC purity documentation.

All BPC-157 supply from RetaLABS is explicitly for in vitro and in vivo laboratory research purposes only. It is not supplied as a therapeutic good, not supplied for human consumption, and no therapeutic claim is implied or expressed. Researchers purchasing BPC-157 from RetaLABS confirm by placing an order that the material is for legitimate laboratory research use.

For reconstitution guidance applicable to laboratory use, see the Peptide Reconstitution and Storage Guide. For combination research involving BPC-157 and TB-500, co-scheduled in June 2024, see the BPC-157 and TB-500 Blend Research Guide.

Additional resources in the BPC-157 and related research cluster:

• BPC-157 Research Guide, mechanism of action, musculoskeletal and gastrointestinal evidence, reconstitution
• BPC-157 Molecular Profile, sequence, molecular weight, CAS number, chemical identifiers
• BPC-157 and TB-500 Blend Research Guide, combination research rationale and protocol considerations
• Research Peptides Legal Status in Australia, TGA scheduling framework and research context
• Peptide Reconstitution and Storage Guide, bacteriostatic water, concentration, stability